Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

Esophageal cancer (EC) is frequently considered a lethal malignancy and is often identified at a later stage. It is one of the major causes of cancer-related deaths globally. The conventional treatment methods like chemotherapy, radiotherapy, and surgery offer limited efficacy and poor clinical outc...

Full description

Saved in:
Bibliographic Details
Published in:Cancer and metastasis reviews 2022-06, Vol.41 (2), p.281-299
Main Authors: Sharma, Tarang, Gupta, Ashna, Chauhan, Ravi, Bhat, Ajaz A., Nisar, Sabah, Hashem, Sheema, Akhtar, Sabah, Ahmad, Aamir, Haris, Mohammad, Singh, Mayank, Uddin, Shahab
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Carcinogenesis
Chemotherapy
Development and progression
Esophageal cancer
Esophagus
Health aspects
Inflammation
Malignancy
Medical prognosis
Microbiomes
Microbiota
Microbiota (Symbiotic organisms)
Molecular modelling
Oncology
Oncology, Experimental
Prognosis
Radiation therapy
Radiotherapy
Squamous cell carcinoma
Tumor microenvironment
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Esophageal cancer (EC) is frequently considered a lethal malignancy and is often identified at a later stage. It is one of the major causes of cancer-related deaths globally. The conventional treatment methods like chemotherapy, radiotherapy, and surgery offer limited efficacy and poor clinical outcome with a less than 25% 5-year survival rate. The poor prognosis of EC persists despite the growth in the development of diagnostic and therapeutic modalities to treat EC. This underlines the need to elucidate the complex molecular mechanisms that drive esophageal oncogenesis. Apart from the role of the tumor microenvironment and its structural and cellular components in tumorigenesis, mounting evidence points towards the involvement of the esophageal microbiome, inflammation, and their cross-talk in promoting esophageal cancer. The current review summarizes recent research that delineates the underlying molecular mechanisms by which the microbiota and inflammation promote the pathophysiology of esophageal cancer, thus unraveling targets for potential therapeutic intervention.
ISSN:0167-7659
1573-7233
DOI:10.1007/s10555-022-10026-6